Mitsubishi Tanabe Pharma said on August 23 that it has submitted a new drug application for a fixed-dose combination containing its sodium glucose co-transporter-2 (SGLT-2) inhibitor Canaglu (canagliflozin) and dipeptidyl peptidase-4 (DPP-4) inhibitor Tenelia (teneligliptin).The once-daily combo drug is expected…
To read the full story
Related Article
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Mitsubishi Tanabe, Daiichi Sankyo Expand Tie-Up to Push DPP-4/SGLT-2 Combo
March 30, 2017
BUSINESS
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
- Enhertu Combo Bags EU Panel Nod in 1st-Line HER2 Breast Cancer
July 28, 2026
- FDA Approves Otsuka’s ADHD Drug Simtriyo
July 28, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





